½ÃÀ庸°í¼­
»óǰÄÚµå
1463655

Áß³²¹Ì ³úô¼ö¾×(CSF) °ü¸® ½ÃÀå : Áö¿ª ºÐ¼® - Á¦Ç°º°, ÃÖÁ¾ »ç¿ëÀÚº° ³úô¼ö¾×°ü¸®

South & Central America Cerebrospinal Fluid Management Market Forecast to 2030 - Regional Analysis - by Product (CSF Shunts and CSF Drainage Systems) and End User (Hospitals, Clinics, Ambulatory Surgical Centers, and Others)

¹ßÇàÀÏ: | ¸®¼­Ä¡»ç: The Insight Partners | ÆäÀÌÁö Á¤º¸: ¿µ¹® 103 Pages | ¹è¼Û¾È³» : Áï½Ã¹è¼Û

    
    
    



¡Ø º» »óǰÀº ¿µ¹® ÀÚ·á·Î Çѱ۰ú ¿µ¹® ¸ñÂ÷¿¡ ºÒÀÏÄ¡ÇÏ´Â ³»¿ëÀÌ ÀÖÀ» °æ¿ì ¿µ¹®À» ¿ì¼±ÇÕ´Ï´Ù. Á¤È®ÇÑ °ËÅ並 À§ÇØ ¿µ¹® ¸ñÂ÷¸¦ Âü°íÇØÁֽñ⠹ٶø´Ï´Ù.

Áß³²¹Ì ³úô¼ö¾×(CSF) °ü¸® ½ÃÀåÀº 2022³â¿¡ 9,252¸¸ ´Þ·¯·Î Æò°¡µÇ¾ú°í, 2030³â¿¡´Â 1¾ï 2,389¸¸ ´Þ·¯¿¡ À̸¦ °ÍÀ¸·Î ¿¹ÃøµÇ¸ç, ¿¹Ãø±â°£ µ¿¾È º¹ÇÕ ¿¬°£ ¼ºÀå·ü(CAGR) 3.7%·Î ¼ºÀåÇÒ °ÍÀ¸·Î ¿¹Ãø ÀÖ½À´Ï´Ù.

½Å°æ Áúȯ Ä¡·á¿¡¼­ ¼ö¾× °ü¸®¿¡ ´ëÇÑ °ü½É Áõ°¡´Â Áß³²¹Ì ³úô¼ö¾×(CSF) °ü¸® ½ÃÀåÀ» µÞ¹Þħ

CSF ¸Å°³º¯¼ö´Â ¼ºÀΠȯÀÚÀÇ ½Å°æ ÁúȯÀÇ ¹ÙÀÌ¿À¸¶Ä¿·Î ³Î¸® Æò°¡µË´Ï´Ù. CSFÀÇ ¼øÈ¯ ¸¶ÀÌÅ©·Î RNA´Â ´Ù¾çÇÑ ½Å°æ ÁúȯÀÇ Áø´Ü¿¡ À¯¸ÁÇÑ ¹ÙÀÌ¿À ¸¶Ä¿ÀÔ´Ï´Ù. ÆÄŲ½¼º´(PD), ¾ËÃ÷ÇÏÀ̸Ӻ´(AD), °£Áú, °æ·Ã µîÀÇ ½Å°æ Áúȯ¿¡¼­´Â Á¾Á¾ CSF ÆÄ¶ó¹ÌÅͰ¡ º¯ÇÕ´Ï´Ù. Nature' ÀâÁö¿¡ °ÔÀçµÈ ³í¹®¿¡ µû¸£¸é PD·Î Áø´Ü¹ÞÀº ȯÀÚ¿¡¼­´Â 76À¯ÇüÀÇ ¼ö¾× ´Ü¹éÁúÀÌ Á¤»óÀο¡ ºñÇØ ±¸Á¶ÀûÀ¸·Î º¯È­Çϰí ÀÖ´Â °ÍÀ¸·Î ¹àÇôÁ³½À´Ï´Ù. ÀÌ ¿¬±¸´Â ¶ÇÇÑÀÌ CSF ´Ü¹éÁúÀÌ Áúº´ Áø´Ü ¹× Ä¡·á¸¦À§ÇÑ ¹ÙÀÌ¿À ¸¶Ä¿·Î »ç¿ëÇÒ ¼ö ÀÖÀ½À» ½Ã»çÇÕ´Ï´Ù. PD´Â ÀÎÁö ±â´É Àå¾Ö¿Í ¿îµ¿ ±â´É ÀúÇϸ¦ µ¿¹ÝÇÑ ½Å°æÅðÇ༺ ÁúȯÀÔ´Ï´Ù. 2022³â¿¡ ¹ßÇ¥µÈ ¼¼°èº¸°Ç±â±¸(WHO) º¸°í¼­¿¡ µû¸£¸é PDÀÇ À¯º´·üÀº Áö³­ 25³â°£ µÎ¹è·Î ´Ã¾úÀ¸¸ç 60¼¼ ÀÌ»óÀÇ ¼¼°è Àα¸ÀÇ ¾à 1%°¡ ¿µÇâÀ» ¹Þ¾Ò½À´Ï´Ù. À¯»çÇϰÔ, ¹ßÀÛÀ̳ª °£Áú »óÅ¿¡ Àִ ȯÀÚ¿¡¼­ ´Ü¹éÁú ¹× ¶ôÆ®»ê ¼öÄ¡¿Í °°Àº ¼ö¾× ¸Å°³º¯¼öÀÇ ÀϺΰ¡ º¯ÇÕ´Ï´Ù. µû¶ó¼­ ¹ßÀÛ°ú °£ÁúÀÇ Ä¡·á¿¡ ¼ö¾× ¸Å°³ º¯¼ö¸¦ »ç¿ëÇϱâ À§ÇØ ´Ù¾çÇÑ ¿¬±¸ °³¹ßÀÌ ÀÌ·ç¾îÁö°í ÀÖ½À´Ï´Ù. ¶ÇÇÑ, CSF¸¦ ÀÌ¿ëÇÑ ¾ËÃ÷ÇÏÀ̸Ӻ´ °ËÃâÀ» À§ÇÑ ´Ù¾çÇÑ CSF °ËÁ¤ÀÌ ½ÃÀå¿¡ ³ª¿Í ÀÖÀ½¿¡µµ ºÒ±¸Çϰí, °ËÃâ ¹× Ä¡·á ¸ñÀûÀÇ ¹ÙÀÌ¿À¸¶Ä¿¿¡ ´ëÇÑ ¿ä±¸´Â ÃæÁ·µÇÁö ¾Ê¾Ò½À´Ï´Ù. ¾ËÃ÷ÇÏÀ̸Ӻ´ ¹× PDÀÇ Áõ·Ê °ËÃâÀÌ Áõ°¡ÇÔ¿¡ µû¶ó ¼ö¾× ´©ÃâÀÇ Áõ·Ê°¡ Áõ°¡ÇÒ ¼ö ÀÖÀ¸¹Ç·Î ¼ö¾× °ü¸® ÀåÄ¡ ¼ö¿ä°¡ Áõ°¡Çϰí ÀÖ½À´Ï´Ù. µû¶ó¼­ ½Å°æÁúȯÀÇ À¯º´·ü Áõ°¡´Â ÀÌ·¯ÇÑ ÁúȯÀÇ Ä¡·á¿¡ ¼ö¾× °ü¸® Á¦Ç°À» »ç¿ëÇϱâ À§ÇÑ ¿¬±¸°³¹ß Ȱµ¿¿¡ ¹ÚÂ÷¸¦ °¡Çϰí ÀÖ½À´Ï´Ù.

Áß³²¹Ì ³úô¼ö¾×(CSF) °ü¸® ½ÃÀå °³¿ä

Áß³²¹Ì ³úô¼ö¾×(CSF) °ü¸® ½ÃÀåÀº ºê¶óÁú, ¾Æ¸£ÇîÆ¼³ª ¹× ±âŸ Áß³²¹Ì·Î ±¸ºÐµË´Ï´Ù. ÀÌ Áö¿ª ½ÃÀå ¼ºÀåÀº ÀÇ·á±â±âÀÇ ¼öÀÔ Áõ°¡, ÷´Ü ÀÇ·á ±â¼úÀ» ÇÊ¿ä·Î ÇÏ´Â ÀÇ·á ½Ã½ºÅÛÀÇ °³¹ß, ³ëÀÎ Àα¸ Áõ°¡·Î ÀÎÇÑ ¿©·¯ ±âȸ¿¡ ±â´ëµË´Ï´Ù.

Áß³²¹Ì ³úô¼ö¾×(CSF) °ü¸® ½ÃÀå ¼öÀͰú ¿¹Ãø(-2030³â)(US$Mn)

Áß³²¹Ì ³úô¼ö¾×(CSF) °ü¸® ½ÃÀåÀÇ ¼¼ºÐÈ­

Áß³²¹Ì ³úô¼ö¾×(CSF) °ü¸® ½ÃÀåÀº Á¦Ç°, ÃÖÁ¾ »ç¿ëÀÚ, ±¹°¡·Î ±¸ºÐµË´Ï´Ù.

Á¦Ç°º°·Î Áß³²¹Ì ³úô¼ö¾×(CSF) °ü¸® ½ÃÀåÀº CSF ¼ÇÆ®¿Í CSF ¹è¼ö ½Ã½ºÅÛÀ¸·Î À̺е˴ϴÙ. 2022³â¿¡´Â CSF ¼ÇÆ® ºÎ¹®ÀÌ Å« ½ÃÀå Á¡À¯À²À» Â÷ÁöÇß½À´Ï´Ù.

ÃÖÁ¾ »ç¿ëÀÚº°·Î º¸¸é Áß³²¹Ì ³úô¼ö¾×(CSF) °ü¸® ½ÃÀåÀº º´¿ø, Ŭ¸®´Ð, ¿Ü·¡¼ö¼ú¼¾ÅÍ(ASC) µîÀ¸·Î ±¸ºÐµË´Ï´Ù. º´¿ø ºÎ¹®Àº 2022³â¿¡ °¡Àå Å« ½ÃÀå Á¡À¯À²À» Â÷ÁöÇß½À´Ï´Ù.

±¹°¡º°·Î º¸¸é Áß³²¹Ì ³úô¼ö¾×(CSF) °ü¸® ½ÃÀåÀº ºê¶óÁú, ¾Æ¸£ÇîÆ¼³ª ¹× ±âŸ Áß³²¹Ì·Î ±¸ºÐµË´Ï´Ù. ºê¶óÁúÀº 2022³â Áß³²¹Ì ³úô¼ö¾×(CSF) °ü¸® ½ÃÀå Á¡À¯À²À» µ¶Á¡Çß½À´Ï´Ù.

B.Braun SE, Integra LifeSciences Holdings Corp, Medtronic Plc, Spiegelberg GmbH &Co KG µîÀº Áß³²¹Ì ³úô¼ö¾×(CSF) °ü¸® ½ÃÀå¿¡¼­ »ç¾÷À» Àü°³Çϰí ÀÖ´Â ´ë±â¾÷ÀÔ´Ï´Ù.

¸ñÂ÷

Á¦1Àå ¼­·Ð

Á¦2Àå ÁÖ¿ä ¿ä¾à

  • ÁÖ¿ä ÀλçÀÌÆ®

Á¦3Àå Á¶»ç ¹æ¹ý

  • Á¶»ç ¹üÀ§
  • 2Â÷ Á¶»ç
  • 1Â÷ Á¶»ç

Á¦4Àå Áß³²¹Ì ³úô¼ö¾×(CSF) °ü¸® ½ÃÀåÀÇ Á¤¼¼

  • Áß³²¹Ì PEST ºÐ¼®

Á¦5Àå Áß³²¹Ì ³úô¼ö¾×(CSF) °ü¸® ½ÃÀå : ÁÖ¿ä »ê¾÷¿ªÇÐ

  • ½ÃÀå ¼ºÀå ÃËÁø¿äÀÎ
    • ³úô¼ö¾× ´©Ãâ Áõ·Ê Áõ°¡
    • ³úô¼ö¾×°ú °ü·ÃµÈ °úÁ¦ Áõ°¡¿¡ ´ëÇÑ Á¤ºÎÀÇ ÀÌ´Ï¼ÅÆ¼ºê
  • ½ÃÀå ¼ºÀå ¾ïÁ¦¿äÀÎ
    • °íÀåÀ̳ª ¿ÀÀÛµ¿ÀÇ À§Çè
  • ½ÃÀå ±âȸ
    • ½Å°æÁúȯ Ä¡·á¿¡ À־ÀÇ ¼ö¾× °ü¸®¿¡ ´ëÇÑ ÁÖ¸ñÀÇ °íÁ¶
  • ÇâÈÄÀÇ µ¿Çâ
    • ½º¸¶Æ® ³úô¼ö¾× ¼ÇÆ® °³¹ß
  • ¿µÇ⠺м®

Á¦6Àå ³úô¼ö¾×(CSF) °ü¸® ½ÃÀå : Áß³²¹Ì ½ÃÀå ºÐ¼®

  • Áß³²¹Ì ³úô¼ö¾×(CSF) °ü¸® ½ÃÀå ¼öÀÍ(2022³â-2030³â)

Á¦7Àå Áß³²¹Ì ³úô¼ö¾×(CSF) °ü¸® ½ÃÀå - ¼öÀͰú ¿¹Ãø(-2030³â) : Á¦Ç°º°

  • ½ÃÀå¼öÀÍ Á¡À¯À²(2022³â, 2030³â)
  • ¼ö¾× ¼ÇÆ®
  • ¼ö¾× ¹è¼ö ½Ã½ºÅÛ

Á¦8Àå Áß³²¹Ì ³úô¼ö¾×(CSF) °ü¸® ½ÃÀå - ¼öÀͰú ¿¹Ãø(-2030³â) : ÃÖÁ¾ »ç¿ëÀÚº°

  • ½ÃÀå¼öÀÍ Á¡À¯À²(2022³â, 2030³â)
  • º´¿ø
  • Áø·á¼Ò
  • ¿Ü·¡¼ö¼ú¼¾ÅÍ(ASC)
  • ±âŸ

Á¦9Àå Áß³²¹Ì ³úô¼ö¾×(CSF) °ü¸® ½ÃÀå : ±¹°¡º° ºÐ¼®

  • Áß³²¹Ì ³úô¼ö¾×(CSF) °ü¸® ½ÃÀå : ±¹°¡º° ºÐ¼®
  • ºê¶óÁú
  • ¾Æ¸£ÇîÆ¼³ª
  • ±âŸ Áß³²¹Ì

Á¦10Àå ¾÷°è Á¤¼¼

  • Áß³²¹Ì ³úô¼ö¾×(CSF) °ü¸® ½ÃÀå¿¡¼­ÀÇ ¼ºÀå Àü·«(2020³â-2023³â)
  • ¹«±âÀû ¼ºÀå Àü·«
  • À¯±âÀû ¼ºÀå Àü·«

Á¦11Àå ±â¾÷ ÇÁ·ÎÆÄÀÏ

  • Medtronic Plc
  • Integra LifeSciences Holdings Corp
  • B. Braun SE
  • Spiegelberg GmbH & Co KG

Á¦12Àå ºÎ·Ï

BJH 24.05.23

The South & Central America cerebrospinal fluid management market was valued at US$ 92.52 million in 2022 and is expected to reach US$ 123.89 million by 2030; it is estimated to grow at a CAGR of 3.7% from 2022 to 2030.

Increasing Focus on CSF Management in Neurological Disease Treatments Fuels the South & Central America Cerebrospinal Fluid Management Market

CSF parameters are extensively evaluated as biomarkers of neurological disorders in adult patients. Circulating microRNAs in CSF are a promising class of biomarkers for the diagnosis of various neurological diseases. Neurological disorders such as Parkinson's Disease (PD), Alzheimer's Disease (AD), epilepsy, and seizures often lead to altered CSF parameters. According to an article published in Nature, 76 CSF proteins were found to be structurally altered in patients that were diagnosed with PD when compared to normal individuals. The study also suggests that these CSF proteins can be used as biomarkers for the diagnosis or treatment of the disease. PD is a neurodegenerative disease associated with loss of cognitive impairment and motor function. According to the World Health Organization (WHO) report published in 2022, the prevalence of PD has doubled in the last 25 years, affecting ~1% of the global population aged more than 60 years. Similarly, a few of the CSF parameters such as protein and lactate levels are altered in patients suffering from seizure or status epilepticus. Therefore, various R&D activities are going on for using CSF parameters in the treatment of seizures or epilepsy. Further, despite the availability of various CSF assays for the detection of Alzheimer's disease using CSF in the market, there are unmet needs for biomarkers for detection and treatment purposes. As the detection of cases of Alzheimer's disease and PD increases, there is increase in demand for CSF management devices as the cases of CSF leaks may increases. Therefore, a rise in the prevalence of neurological disorders is fueling the research and development activities for the use of CSF management products in the treatment of these disorders.

South & Central America Cerebrospinal Fluid Management Market Overview

The cerebrospinal fluid management market in South & Central America is segmented into Brazil, Argentina, and the Rest of South & Central America. The growth of the market in the region is expected due to several opportunities offered by increasing import of medical devices, growing developments of healthcare systems that demand advanced medical technologies and growing geriatric population.

South & Central America Cerebrospinal Fluid Management Market Revenue and Forecast to 2030 (US$ Mn)

South & Central America Cerebrospinal Fluid Management Market Segmentation

The South & Central America cerebrospinal fluid management market is segmented into product, end user and country.

Based on product, the South & Central America cerebrospinal fluid management market is bifurcated into CSF shunts and CSF drainage systems. The CSF shunts segment held a larger market share in 2022.

Based on end user, the South & Central America cerebrospinal fluid management market is segmented into hospitals, clinics, ambulatory surgical centers, and others. The hospitals segment held the largest market share in 2022.

Based on country, the South & Central America cerebrospinal fluid management market is segmented into Brazil, Argentina, and the Rest of South & Central America. Brazil dominated the South & Central America cerebrospinal fluid management market share in 2022.

B. Braun SE, Integra LifeSciences Holdings Corp, Medtronic Plc, and Spiegelberg GmbH & Co KG are some of the leading companies operating in the South & Central America cerebrospinal fluid management market.

Table Of Contents

1. Introduction

  • 1.1 The Insight Partners Research Report Guidance
  • 1.2 Market Segmentation

2. Executive Summary

  • 2.1 Key Insights

3. Research Methodology

  • 3.1 Coverage
  • 3.2 Secondary Research
  • 3.3 Primary Research

4. South & Central America Cerebrospinal Fluid Management Market Landscape

  • 4.1 Overview
  • 4.2 South & Central America PEST Analysis

5. South & Central America Cerebrospinal Fluid Management Market - Key Industry Dynamics

  • 5.1 Market Drivers
    • 5.1.1 Increasing Cases of Cerebrospinal Fluid Leaks
    • 5.1.2 Government Initiatives for Addressing Growing Challenges Associated with CSF
  • 5.2 Market Restraints
    • 5.2.1 Risk of Failure and Malfunctioning
  • 5.3 Market Opportunities
    • 5.3.1 Increasing Focus on CSF Management in Neurological Disease Treatments
  • 5.4 Future Trends
    • 5.4.1 Development of Smart Cerebrospinal Fluid Shunts
  • 5.5 Impact Analysis:

6. Cerebrospinal Fluid Management Market - South & Central America Market Analysis

  • 6.1 South & Central America Cerebrospinal Fluid Management Market Revenue (US$ Mn), 2022 - 2030

7. South & Central America Cerebrospinal Fluid Management Market - Revenue and Forecast to 2030 - by Product

  • 7.1 Overview
  • 7.2 South & Central America Cerebrospinal Fluid Management Market Revenue Share, by Product 2022 & 2030 (%)
  • 7.3 CSF Shunts
    • 7.3.1 Overview
    • 7.3.2 CSF Shunts: South & Central America Cerebrospinal Fluid Management Market - Revenue and Forecast to 2030 (US$ Million)
    • 7.3.3 Ventriculoperitoneal Shunts
      • 7.3.3.1 Overview
      • 7.3.3.2 Ventriculoperitoneal Shunts: South & Central America Cerebrospinal Fluid Management Market - Revenue and Forecast to 2030 (US$ Million)
    • 7.3.4 Ventriculoatrial Shunts
      • 7.3.4.1 Overview
      • 7.3.4.2 Ventriculoatrial Shunts: South & Central America Cerebrospinal Fluid Management Market - Revenue and Forecast to 2030 (US$ Million)
    • 7.3.5 Ventriculopleural Shunts
      • 7.3.5.1 Overview
      • 7.3.5.2 Ventriculopleural Shunts: South & Central America Cerebrospinal Fluid Management Market - Revenue and Forecast to 2030 (US$ Million)
    • 7.3.6 Lumboperitoneal Shunts
      • 7.3.6.1 Overview
      • 7.3.6.2 Lumboperitoneal Shunts: South & Central America Cerebrospinal Fluid Management Market - Revenue and Forecast to 2030 (US$ Million)
  • 7.4 CSF Drainage Systems
    • 7.4.1 Overview
    • 7.4.2 CSF Drainage Systems: South & Central America Cerebrospinal Fluid Management Market - Revenue and Forecast to 2030 (US$ Million)
    • 7.4.3 External Ventricular Drainage (EVD) Systems
      • 7.4.3.1 Overview
      • 7.4.3.2 External Ventricular Drainage (EVD) Systems: South & Central America Cerebrospinal Fluid Management Market - Revenue and Forecast to 2030 (US$ Million)
    • 7.4.4 Lumbar Drainage (LD) Systems
      • 7.4.4.1 Overview
      • 7.4.4.2 Lumbar Drainage (LD) Systems: South & Central America Cerebrospinal Fluid Management Market - Revenue and Forecast to 2030 (US$ Million)

8. South & Central America Cerebrospinal Fluid Management Market - Revenue and Forecast to 2030 - by End User

  • 8.1 Overview
  • 8.2 South & Central America Cerebrospinal Fluid Management Market Revenue Share, by End User 2022 & 2030 (%)
  • 8.3 Hospitals
    • 8.3.1 Overview
    • 8.3.2 Hospitals: South & Central America Cerebrospinal Fluid Management Market - Revenue and Forecast to 2030 (US$ Million)
  • 8.4 Clinics
    • 8.4.1 Overview
    • 8.4.2 Clinics: South & Central America Cerebrospinal Fluid Management Market - Revenue and Forecast to 2030 (US$ Million)
  • 8.5 Ambulatory Surgical Centers
    • 8.5.1 Overview
    • 8.5.2 Ambulatory Surgical Centers: South & Central America Cerebrospinal Fluid Management Market - Revenue and Forecast to 2030 (US$ Million)
  • 8.6 Others
    • 8.6.1 Overview
    • 8.6.2 Others: South & Central America Cerebrospinal Fluid Management Market - Revenue and Forecast to 2030 (US$ Million)

9. South & Central America Cerebrospinal Fluid Management Market - Country Analysis

  • 9.1 Overview
      • 9.1.1.1 South & Central America Cerebrospinal Fluid Management Market, by Country
      • 9.1.1.2 Brazil
        • 9.1.1.2.1 Overview
        • 9.1.1.2.2 Brazil: South & Central America Cerebrospinal Fluid Management Market Revenue and Forecast to 2030 (US$ Mn)
        • 9.1.1.2.3 Brazil: South & Central America Cerebrospinal Fluid Management Market, by Product
        • 9.1.1.2.3.1 Brazil: South & Central America Cerebrospinal Fluid Management Market, by CSF Shunts
        • 9.1.1.2.3.2 Brazil: South & Central America Cerebrospinal Fluid Management Market, by CSF Drainage Systems
        • 9.1.1.2.4 Brazil: South & Central America Cerebrospinal Fluid Management Market, by End User
      • 9.1.1.3 Argentina
        • 9.1.1.3.1 Overview
        • 9.1.1.3.2 Argentina: South & Central America Cerebrospinal Fluid Management Market Revenue and Forecast to 2030 (US$ Mn)
        • 9.1.1.3.3 Argentina: South & Central America Cerebrospinal Fluid Management Market, by Product
        • 9.1.1.3.3.1 Argentina: South & Central America Cerebrospinal Fluid Management Market, by CSF Shunts
        • 9.1.1.3.3.2 Argentina: South & Central America Cerebrospinal Fluid Management Market, by CSF Drainage Systems
        • 9.1.1.3.4 Argentina: South & Central America Cerebrospinal Fluid Management Market, by End User
      • 9.1.1.4 Rest of South & Central America
        • 9.1.1.4.1 Overview
        • 9.1.1.4.2 Rest of South & Central America: South & Central America Cerebrospinal Fluid Management Market Revenue and Forecast to 2030 (US$ Mn)
        • 9.1.1.4.3 Rest of South & Central America: South & Central America Cerebrospinal Fluid Management Market, by Product
        • 9.1.1.4.3.1 Rest of South & Central America: South & Central America Cerebrospinal Fluid Management Market, by CSF Shunts
        • 9.1.1.4.3.2 Rest of South & Central America: South & Central America Cerebrospinal Fluid Management Market, by CSF Drainage Systems
        • 9.1.1.4.4 Rest of South & Central America: South & Central America Cerebrospinal Fluid Management Market, by End User

10. Industry Landscape

  • 10.1 Overview
  • 10.2 Growth Strategies in The South & Central America Cerebrospinal Fluid Management Market, 2020-2023
  • 10.3 Inorganic Growth Strategies
    • 10.3.1 Overview
  • 10.4 Organic Growth Strategies
    • 10.4.1 Overview

11. Company Profiles

  • 11.1 Medtronic Plc
    • 11.1.1 Key Facts
    • 11.1.2 Business Description
    • 11.1.3 Products and Services
    • 11.1.4 Financial Overview
    • 11.1.5 SWOT Analysis
    • 11.1.6 Key Developments
  • 11.2 Integra LifeSciences Holdings Corp
    • 11.2.1 Key Facts
    • 11.2.2 Business Description
    • 11.2.3 Products and Services
    • 11.2.4 Financial Overview
    • 11.2.5 SWOT Analysis
    • 11.2.6 Key Developments
  • 11.3 B. Braun SE
    • 11.3.1 Key Facts
    • 11.3.2 Business Description
    • 11.3.3 Products and Services
    • 11.3.4 Financial Overview
    • 11.3.5 SWOT Analysis
    • 11.3.6 Key Developments
  • 11.4 Spiegelberg GmbH & Co KG
    • 11.4.1 Key Facts
    • 11.4.2 Business Description
    • 11.4.3 Products and Services
    • 11.4.4 Financial Overview
    • 11.4.5 SWOT Analysis
    • 11.4.6 Key Developments

12. Appendix

  • 12.1 About Us
  • 12.2 Glossary of Terms
»ùÇà ¿äû ¸ñ·Ï
0 °ÇÀÇ »óǰÀ» ¼±Åà Áß
¸ñ·Ï º¸±â
Àüü»èÁ¦